PROCTER & GAMBLE HEALTH | ISHITA DRUGS | PROCTER & GAMBLE HEALTH/ ISHITA DRUGS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 32.6 | 106.1% | View Chart |
P/BV | x | 10.6 | 2.3 | 459.6% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH ISHITA DRUGS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
ISHITA DRUGS Mar-23 |
PROCTER & GAMBLE HEALTH/ ISHITA DRUGS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 80 | 6,744.9% | |
Low | Rs | 3,883 | 40 | 9,830.4% | |
Sales per share (Unadj.) | Rs | 740.7 | 40.4 | 1,834.7% | |
Earnings per share (Unadj.) | Rs | 138.2 | 1.9 | 7,163.3% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 2.4 | 6,562.0% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 30.7 | 1,459.0% | |
Shares outstanding (eoy) | m | 16.60 | 2.99 | 555.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 1.5 | 423.4% | |
Avg P/E ratio | x | 33.5 | 30.8 | 108.5% | |
P/CF ratio (eoy) | x | 29.8 | 25.2 | 118.3% | |
Price / Book Value ratio | x | 10.3 | 1.9 | 532.4% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 178 | 43,124.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 8 | 26,637.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 121 | 10,185.7% | |
Other income | Rs m | 184 | 2 | 9,149.3% | |
Total revenues | Rs m | 12,480 | 123 | 10,168.7% | |
Gross profit | Rs m | 3,247 | 8 | 42,608.9% | |
Depreciation | Rs m | 281 | 1 | 21,782.9% | |
Interest | Rs m | 8 | 1 | 1,425.9% | |
Profit before tax | Rs m | 3,142 | 8 | 40,333.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 2 | 41,945.5% | |
Profit after tax | Rs m | 2,295 | 6 | 39,769.5% | |
Gross profit margin | % | 26.4 | 6.3 | 418.5% | |
Effective tax rate | % | 27.0 | 25.9 | 104.0% | |
Net profit margin | % | 18.7 | 4.8 | 390.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 102 | 11,508.0% | |
Current liabilities | Rs m | 6,791 | 20 | 33,568.0% | |
Net working cap to sales | % | 40.0 | 67.6 | 59.3% | |
Current ratio | x | 1.7 | 5.0 | 34.3% | |
Inventory Days | Days | 263 | 105 | 251.0% | |
Debtors Days | Days | 343 | 54,431,599 | 0.0% | |
Net fixed assets | Rs m | 10,617 | 12 | 86,316.3% | |
Share capital | Rs m | 166 | 30 | 555.2% | |
"Free" reserves | Rs m | 7,265 | 62 | 11,749.2% | |
Net worth | Rs m | 7,431 | 92 | 8,100.4% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 114 | 19,575.4% | |
Interest coverage | x | 409.1 | 15.4 | 2,651.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 1.1 | 52.0% | |
Return on assets | % | 10.3 | 5.5 | 186.4% | |
Return on equity | % | 30.9 | 6.3 | 490.6% | |
Return on capital | % | 42.4 | 9.1 | 466.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 17 | 8,377.4% | |
Fx outflow | Rs m | 1,605 | 0 | 698,000.0% | |
Net fx | Rs m | -140 | 17 | -812.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | -29 | -8,146.4% | |
From Investments | Rs m | -215 | 6 | -3,619.5% | |
From Financial Activity | Rs m | -985 | 11 | -9,378.1% | |
Net Cashflow | Rs m | 1,160 | -13 | -9,252.8% |
Indian Promoters | % | 0.0 | 49.4 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 0.0 | - | |
FIIs | % | 6.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 50.6 | 95.3% | |
Shareholders | 56,778 | 5,351 | 1,061.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | ISHITA DRUGS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 1.00% | 0.45% |
1-Month | -1.15% | 12.20% | 2.55% |
1-Year | 0.73% | 40.87% | 56.14% |
3-Year CAGR | -8.76% | 26.75% | 15.22% |
5-Year CAGR | 4.97% | 28.65% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the ISHITA DRUGS share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of ISHITA DRUGS the stake stands at 49.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of ISHITA DRUGS.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
ISHITA DRUGS paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of ISHITA DRUGS.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.